Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
Defence Therapeutics has received a 30-day extension from the Canadian Securities Exchange for its non-brokered private placement offering. The company previously closed a first tranche of 1,550,000 units at $0.50 per unit, raising $775,000. The upcoming financing will partially fund the development of Defence's preclinical radiopharmaceuticals and ADC programs, which utilize their proprietary Accum® technology platform. Both programs aim to enhance cancer treatment efficacy by delivering radioactivity/drugs more precisely to cancer cells, potentially reducing dosing requirements and side effects for patients.
Defence Therapeutics ha ricevuto un'estensione di 30 giorni dalla Borsa Valori canadese per la sua offerta di collocamento privato non mediato. La società ha precedentemente chiuso una prima tranche di 1.550.000 unità a $0,50 per unità, raccogliendo $775.000. Il finanziamento imminente finanzierà parzialmente lo sviluppo dei radiofarmaci preclinici e dei programmi ADC di Defence, che utilizzano la loro piattaforma tecnologica proprietaria Accum®. Entrambi i programmi mirano a migliorare l'efficacia del trattamento del cancro, fornendo radioattività/farmaci in modo più preciso alle cellule cancerose, potenzialmente riducendo i requisiti di dosaggio e gli effetti collaterali per i pazienti.
Defence Therapeutics ha recibido una extensión de 30 días de la Bolsa de Valores de Canadá para su oferta de colocación privada no intermediada. La empresa había cerrado previamente una primera tranche de 1.550.000 unidades a $0,50 por unidad, recaudando $775.000. La financiación próxima ayudará parcialmente a financiar el desarrollo de los radiofármacos preclínicos y los programas ADC de Defence, que utilizan su plataforma tecnológica propietaria Accum®. Ambos programas tienen como objetivo mejorar la eficacia del tratamiento del cáncer al administrar radioactividad/fármacos de manera más precisa a las células cancerosas, lo que podría reducir los requisitos de dosificación y los efectos secundarios para los pacientes.
Defence Therapeutics는 캐나다 증권 거래소로부터 비중개 사모펀드 개시를 위한 30일 연장을 받았습니다. 이 회사는 이전에 1,550,000개의 유닛을 각 $0.50에 1차로 종료하여 $775,000을 조달했습니다. 다가오는 자금 조달은 Defence의 임상 전 방사성 의약품 및 ADC 프로그램 개발의 일부를 지원할 것입니다. 이 프로그램들은 고유한 Accum® 기술 플랫폼을 활용하여 방사선/약물을 더 정밀하게 암세포에 전달함으로써 암 치료의 효능을 강화하고 잠재적으로 환자의 복용량 요구 사항과 부작용을 줄이는 것을 목표로 하고 있습니다.
Defence Therapeutics a reçu une extension de 30 jours de la Bourse canadienne pour son offre de placement privé sans intermédiaire. La société a précédemment clôturé une première tranche de 1 550 000 unités à 0,50 $ l'unité, levant ainsi 775 000 $. Le financement à venir financera partiellement le développement des radio-pharmaceutiques précliniques et des programmes ADC de Defence, qui utilisent leur plateforme technologique propriétaire Accum®. Les deux programmes visent à améliorer l'efficacité du traitement du cancer en délivrant des radioactivités/médicaments de manière plus précise aux cellules cancéreuses, réduisant potentiellement les besoins en posologie et les effets secondaires pour les patients.
Defence Therapeutics hat von der kanadischen Börse eine 30-tägige Fristverlängerung für ihr nicht-brokergeführtes Private Placement erhalten. Das Unternehmen hat zuvor eine erste Tranche von 1.550.000 Einheiten zu je $0,50 abgeschlossen und dabei $775.000 gesammelt. Die bevorstehende Finanzierung wird teilweise die Entwicklung der präklinischen Radiopharmazeutika und ADC-Programme von Defence unterstützen, die ihre proprietäre Accum®-Technologieplattform nutzen. Beide Programme zielen darauf ab, die Wirksamkeit der Krebsbehandlung zu verbessern, indem sie Radioaktivität/Arzneimittel präziser an Krebszellen abgeben, was möglicherweise die Dosierungsanforderungen und Nebenwirkungen für die Patienten reduzieren könnte.
- Successfully raised $775,000 in first tranche of private placement
- Secured 30-day extension for additional funding
- Requires additional financing through private placement to fund operations
- Programs still in preclinical stage with no immediate revenue potential
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension approval from Canadian Securities Exchange to extend the closing for the balance of its previously announced non-brokered private placement of units of the Company (the "Units") at a price of
The Company wished to inform that a portion of the upcoming tranche of financing will be allocated to further develop Defence's preclinical radiopharmaceuticals program as well as the ADCs program using its proprietary Accum® technology platform. Those two very promising programs are at the center of Defence's preclinical development, and both have similar objectives which are to deliver the radioactivity/drugs specifically and more precisely to cancer cells, resulting in increasing the efficacy to treat cancers, with potentially to significantly reducing the dosing and causing less sides effects for the benefit of the cancer patients.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228877
FAQ
How much did Defence Therapeutics (DTCFF) raise in the first tranche of its private placement?
What is the price per unit for Defence Therapeutics' (DTCFF) private placement offering?
What will Defence Therapeutics (DTCFF) use the private placement proceeds for?
